医保药品目录动态调整下药企应对策略——以A企业肺癌靶向药为例

目的:以A企业肺癌三代靶向药为例,分析药品企业应对医保药品目录动态调整的策略。方法:采用半结构化访谈法了解相关人员对医保政策调整的看法,通过问卷调查法了解患者用药满意度的变化,通过典型案例分析靶向药纳入医保目录前后的销售变化情况。结果:药品纳入医保目录后,药品价格显著下降,销售量显著上升,患者用药满意度明显提升。结论:企业应继续完善公司战略,加大创新研发力度,稳定药品质量和疗效,积极应对新一轮国家医保药品目录调整。

肺癌靶向药治疗所致腹泻的中医治疗研究进展

肺癌也是最常见的恶性肿瘤中的之一,在医学上的诊断手段主要以药物、化疗和放疗为主,但较难取得令人满意的临床效。除常规的放化疗,靶向药物临床用药及趋势正逐年增加,但其出现的毒副作用为患者的治疗带来了另一种危害,甚至会导致部分患者无法坚持治疗,影响最后疗效。虽然靶向药的损害比传统治疗伤害程度减低,但是也会导致严重的不良反应,包括皮肤,消化道,肝毒性等也逐渐受到人们重视,需要更深入的探究。在中医,尤其是在肺癌靶向疗法后所出现的严重不良反应腹泻,疗效甚佳。我们要进一步总结和完善的原则,进行规范化的治疗,也要推动中医药科技的成熟与发展,能够有效的改善病人的预后和生活质量。本文主要对肺癌的靶向药治疗后腹泻发病情况、发病机制及中医治疗方法等多方面综述,为今后中西医治疗肺癌靶向药腹泻提供理论参考予以综述。

Antiangiogenic agents combined with chemotherapy in non-small cell lung cancer

As a targeted therapy, antiangiogenic treatment has been increasingly studied for advanced non-small cell lung cancer(NSCLC) and has proven effective for the treatment of advanced NSCLC. Bevacizumab, a monoclonal antibody targeting angiogenesis, is the only antiangiogenic agent approved for use in combination with first-line chemotherapy for non-squamous NSCLC. Small-molecule inhibitors targeting the tyrosine kinase receptor have also shown promise when combined with standard chemotherapeutic agents in patients with advanced NSCLC. However, unlike bevacizumab, not all other antiangiogenic agents show significant benefits when combined with chemotherapy. As for the failures of most other combinations, the combination schedule may be an important reason that has so far been overlooked in clinical trials. This article reviews the combination of angiogenic agents with chemotherapy in the treatment of NSCLC.